• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Elixir Medical Corporation

Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent

May 23, 2025 By Sean Whooley

Elixir-Dynamx

Elixir Medical announced three-year results from a large randomized controlled trial of its DynamX coronary bioadaptor system. The 445-patient BIOADAPTOR trial compares DynamX to the standard of care Medtronic Resolute Onyx drug-eluting stent (DES). It took place across 34 centers in Japan, Europe and New Zealand. Data — shared this week at EuroPCR 2025 in […]

Filed Under: Cardiovascular, Clinical Trials, Implants, Stents Tagged With: Elixir Medical Corporation

Elixir Medical has positive data for drug-eluting bioadaptive implant

October 29, 2024 By Sean Whooley

Elixir-Dynamx

Elixir Medical announced positive data demonstrating the benefit of its DynamX coronary bioadaptor system in target lesion failure (TLF). Data highlighted the success of DynamX compared to Medtronic’s Resolute Onyx zotarolimus drug-eluting stent (DES). The study looked at complex patient populations within the INFINITY-SWEDEHEART randomized controlled trial. Data included an analysis of patients with acute […]

Filed Under: Clinical Trials, Drug-Device Combinations, Implants, Stents Tagged With: Elixir Medical Corporation

Elixir Medical wins FDA breakthrough nod for sirolimus-eluting bioadaptor system

June 18, 2024 By Sean Whooley

dynamx-elixir

Elixir Medical announced today that it received FDA breakthrough device designation for its DynamX bioadaptive implant. The breakthrough nod covers the improvement of coronary luminal diameter, restoration of hemodynamic modulation and reduction of plaque progression in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. It follows a March […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Elixir Medical Corporation

EuroPCR 2019: Elixir Medical touts DynamX

May 23, 2019 By Brad Perriello

Elixir Medical's DynamX stent

Elixir Medical touted clinical and imaging results from a study of its DynamX drug-eluting stent, which is designed to restore normal pulsatility and adaptive remodeling in blood vessels after treating a coronary lesion. DynamX, introduced in 2017 at the annual Transcatheter Cardiovascular Therapeutics meeting, is a cobalt-chromium stent with a biodegradable polymer coating that releases […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Stents Tagged With: Biotronik, corindus, Elixir Medical Corporation, EuroPCR 2019

Elixir Medical unveils ‘bioadaptive’ metallic drug-eluting stent at TCT 2017

October 31, 2017 By Sarah Faulkner

Elixir Medical DynamX

Interventional cardiologists have used stents to keep the heart’s coronary arteries open for decades. Transitioning from bare-metal stents to drug-eluting stents in the early 2000s brought tremendous benefits for patients. “But over the last 10 years, the technological progress and meaningful clinical improvements have plateaued,” Elixir Medical CEO Motasim Sirhan told Drug Delivery Business News. “When you stent an artery […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Stents, Vascular Tagged With: Elixir Medical Corporation

European task force: Docs should favor drug-eluting stents over bioresorbable scaffolds

October 12, 2017 By Sarah Faulkner

Abbott

Physicians should not use bioresorbable scaffolds in place of current-generation drug-eluting stents, according to a report from the European Society of Cardiology and European Association of Percutaneous Cardiovascular Inventions. The ECS/EAPCI report says that as long as concerns remain about the increased risk of myocardial infarction and scaffold thrombosis linked with bioresorbable scaffolds, physicians should […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Abbott Laboratories, Biotronik, Boston Scientific, Elixir Medical Corporation, Reva Medical

Reva Medical wins CE Mark for Fantom bioresorbable scaffold

April 4, 2017 By Sarah Faulkner

Reva Medical

Reva Medical (ASX:RVA) said yesterday that it won CE Mark approval in the European Union for its Fantom sirolimus-eluting bioresorbable coronary scaffold. The Fantom scaffold is the San Diego, Calif.-based company’s 1st commercial product. Reva said it plans to begin selling the product in Europe this quarter. “CE Mark approval for Fantom is a major milestone for […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Regulatory/Compliance, Vascular, Wall Street Beat Tagged With: Abbott Laboratories, Biotronik, Elixir Medical Corporation, Reva Medical

Elixir Medical’s DeSyne stent tops Medtronic’s Endeavor after 5 years

February 28, 2017 By Sarah Faulkner

Elixir Medical‘s novolimus-eluting stent, DeSyne, outperformed Medtronic‘s (NYSE:MDT) zotarolimus-eluting stent, Endeavor, according to long-term data from Elixir’s Excella II trial. The study enrolled 210 patients with 2 or more de novo lesions in 2 different epicardial vessels. Researchers randomly assigned patients in a 2:1 ratio to the novolimus-eluting stent or the zotarolimus-eluting stent. The device emits a low […]

Filed Under: Clinical Trials, Featured, Vascular, Wall Street Beat Tagged With: Elixir Medical Corporation, Medtronic

Akesys, Elixir Medical tout 1st implant for Prava bioresorbable peripheral stent

October 20, 2016 By Sarah Faulkner

Elixir Medical, Akesys Medical

Akesys Medical and Elixir Medical Corporation said today that it implanted its 1st Prava sirolimus eluting bioresorbable peripheral scaffold for the treatment of blockages in the superficial femoral artery. The scaffold was developed to keep the large artery in the thigh open and restore blood flow to the leg and resorb into the body, making […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Stents Tagged With: Akesys Medical, Elixir Medical Corporation

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS